Skip to main content
Caplight Logo









Nanyang Biologics

Nanyang Biologics

Private
SingaporeHealthcare & Life Scienceshttps://www.nanyangbiologics.com/

Last Round

M&A

Oct 2, 2025

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Nanyang Biologics is a biotechnology company that provides an AI-driven drug discovery and nature-derived therapeutic platform for longevity and disease treatment.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, Platform-as-a-Service

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Subscription SaaS

AI Layer

Application

Keywords

AI drug discoverydrug discovery platformnatural product discoverygenerative biologycomputational drug discoverynutraceutical discoveryin silico drug discoverygraph neural networkbio-AIDTIGNPlatform-as-a-ServicePaaSpreclinical therapeuticsDrug-Target Interaction Graph Neural Networkfunctional food ingredientsshared IP model

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nanyang Biologics Comparables

Compare Nanyang Biologics with similar companies based on industry and business-model similarity.

Nanyang Biologics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Enveda Biosciences
81%
Kapoose Creek Bio
81%
Brightseed
80%

Nanyang Biologics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
M&AOct 2, 2025
StrategicJul 16, 2024

Key People

Founding team and executive leadership

Winifred Yau

Chief Executive Officer

Executive Team

Duy Trieu

CTO NYB.AI, Founding Member

Founding Team

Teck King LIM

Chief Financial Officer

Executive Team

Nanyang Biologics Investors

Notable investors and investment history

Nanyang Biologics investors
InvestorRounds
Mercatus CapitalSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 2, 2026

    Grew 28% QoQ, from 29 to 37 employees.

  • Aug 1, 2026

    Grew 40% QoQ, from 25 to 35 employees.

Nanyang Biologics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Nanyang Biologics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Nanyang Biologics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSingapore
Employee Range37
Year Founded2020
Last FundingOct 2, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?